The FDA has added a new boxed warning to febuxostat due an increased risk of cardiovascular and all-cause mortality compared with allopurinol, according to a recent safety announcement.
Clinicians have been advised to reserve febuxostat (Uloric, Takeda) for use among patients with gout who have failed or do not otherwise tolerate maximally-titrated allopurinol.
This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
American Society of Nephrology Annual Meeting
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.